4 days ago · BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with metastatic colorectal cancer with a BRAF V600E mutation BRAFTOVI combination regimen received accelerated approval for treatment-naïve patients in December 2024 Results to be shared with the U.S. FDA to ...

Jan 25, 2025 · Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.

Sep 23, 2024 · A phase Ib/II trial of combined BRAF and EGFR inhibition in BRAF V600E positive metastatic colorectal cancer and other cancers: the EVICT (Erlotinib and Vemurafenib In Combination Trial)...

Jan 27, 2025 · Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 ...

Sep 30, 2019 · In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E–mutated metastatic colorectal cancer who had had disease progression after one or two previous regimens.

Phenotypically BRAF V600E mutated mCRC is associated with right-sided cancer. In the above-mentioned report, there were 22.6% of BRAF mutations in the right-side colon cancer vs. only 5.1% in the left-side colon cancer.

Scientists have identified many different types of BRAF mutations. One of the most common types is the BRAF V600E mutation. The name V600E describes the nature and location of the mutation: V and E represent the amino acids (building blocks of protein) that mutated. In this case, valine (V) got replaced by glutamic acid (E).

Mar 19, 2024 · Approximately one in five patients with CRC present with metastatic disease at diagnosis. The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer (mCRC), and is characterised by an aggressive clinical course and poor prognosis.

May 3, 2022 · Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint inhibitors. Worldwide, colorectal cancer (CRC) is the third most common cancer and the second highest cause of cancer-related mortality.

Jan 1, 2017 · Purpose: Mutation of BRAF at the valine 600 residue occurs in approximately 10% of colorectal cancers, a group with particularly poor prognosis. The response of BRAF mutant colorectal cancer to recent targeted strategies such as anti-BRAF or combinations with MEK and EGFR inhibitors remains limited and highly heterogeneous within BRAF V600E ...